We recently published our article Top 5 Medical Robotics Stocks to Buy Today. To read the full article, head on to Top 10 Medical Robotics Stocks to Buy Today. In this piece, we take a closer look at Zimmer Biomet Holdings Inc. (NYSE:ZBH) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
A September review in JAMA Network Open offers a timely reminder that a treatment’s everyday use does not settle every question about its safety. Looking across 110 clinical trials involving 22,608 patients, researchers found a possible signal of higher mortality among patients given the antibiotic cefepime compared with those given other β-lactam antibiotics. Deaths were recorded in 6.6% of the cefepime group and 6.2% of the comparison group. The overall estimate carried uncertainty, and the review did not establish that cefepime caused the difference.
The finding is about an antibiotic, not a surgical robot. Its relevance to medical robotics stocks is the standard it highlights: healthcare innovations have to earn trust through evidence and patient outcomes, not just impressive technology. A machine may offer greater precision or help a hospital work more efficiently, but investors should still ask whether clinicians use it regularly and whether its benefits hold up in practice.
Medical Robots Are Doing More Than Assisting Surgeons
The phrase medical robotics tends to bring one image to mind: mechanical arms working over a patient in an operating room. The field is considerably wider. Robotic systems can help surgeons guide instruments through small incisions, assist in joint replacement and spine procedures, direct radiation beams toward tumors, or help pharmacies manage medicines. These applications serve different parts of healthcare, which is why companies grouped together as healthcare robotics stocks can have very different customers and sources of revenue.
There is a detail behind the term robotic surgery that surprises some readers: in most robotic-assisted operations, the machine is not operating on its own. The surgeon controls the instruments. That makes training, hospital workflow and the number of procedures performed just as important to the commercial story as the robot itself.
For Investors, Usage Matters as Much as Innovation
Selling a robot to a hospital is a milestone; seeing it used consistently is a stronger test. Hospitals must justify the purchase, clinicians must become comfortable with the system, and patients must benefit from the care it helps deliver. Frequent use can also support continuing sales of instruments, supplies and services. The same practical questions apply to robotic cancer treatment and pharmacy automation: does the technology solve a problem often enough to sustain a business?
That is the focus of this ranking of the top 10 medical robotics stocks to buy today. It moves from smaller, riskier opportunities to companies with more established commercial operations, weighing recent developments alongside adoption, financial performance and investment risk. In a field full of striking demonstrations, the most important question is what happens after the demonstration ends.
CHECK THIS OUT: 10 Best Cheap AI Medicine Stocks to Buy Now and Top 10 Healthcare Stocks to Buy With $1000 in 2026.
Our Methodology
To come up with our article the Top 10 Medical Robotics Stocks to Buy Today, Ranked From 10 to 1, we ranked NYSE- and Nasdaq-listed companies by their exposure to medical robotics, commercial adoption, recent developments, financial performance and investment risk.
Top 5 Medical Robotics Stocks to Buy Today
5. Zimmer Biomet Holdings Inc. (NYSE:ZBH)
Current Stock Price as of Writing: $89.69
An established knee robotics business could gain another product, provided the next launch delivers.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) already competes in orthopedic robotics through its ROSA platform. For hospitals, the attraction of systems like ROSA is their role in planning and guiding joint replacement procedures. For investors, the attraction is the possibility that robot adoption also supports the company’s broader orthopedic product business.
The next development is its Monogram robotic technology. On September 8, Zimmer Biomet Holdings, Inc. (NYSE: ZBH) said it would expand its specialized robotics salesforce ahead of an expected 2027 launch of a next-generation Monogram orthopedic robot. The word expected matters: the launch, hospital uptake and financial contribution still lie ahead.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) takes fifth place for its existing robotics presence and identifiable next catalyst. Its stock also depends heavily on how well it executes across its larger orthopedic business. A promising robot pipeline does not erase the need to deliver dependable overall growth.
YOU MUST READ THIS: 10 Fast-Growing AI Healthcare Companies to Watch Right Now
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
